Close this search box.

Avicenna: Using machine learning to skip the hit-to-lead phase

ARTICLE | Emerging Company Profile

Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compounds

By Danielle Golovin, Senior Biopharma Analyst

May 8, 2024 6:01 PM UTC

Avicenna is applying its machine learning platform to medicinal chemistry to accelerate small molecule development, essentially skipping the lengthy hit-to-lead phase and instead going directly to optimizing a clinical candidate.

Companies can spend several years and millions of dollars finding a hit compound that works well in vitro, only to run into issues with off-target toxicity, poor PK or suboptimal tissue distribution in vivo